Periodic Reporting for period 1 - expressPIK (expressTEC - From Launch to First MVP)
Periodo di rendicontazione: 2023-07-01 al 2024-06-30
expressTEC is a forward-looking biotech startup co-founded by Ana Teresa Maia, CEO, and Joana Xavier, CTO, with over 35 years of combined experience in cancer research. The company is dedicated to providing patients with easy access to precise, personalized cancer therapy. To this end, expressTEC is developing innovative RNA-based technologies to revolutionize clinical testing, ensuring that cancer patients are accurately and efficiently selected for targeted therapies. Our ultimate goal is to optimize treatment outcomes, reduce side effects, and significantly improve the quality of life for cancer patients.
The Women TechEU Award has been crucial in supporting the initial stages of expressTEC’s development. Throughout the project, the following key activities and achievements were realized:
- Investment and Resource Acquisition: expressTEC secured vital funding, including €100K from Portugal Ventures and over €65K in pitching awards. These funds were pivotal in advancing our research and development efforts and enhancing our visibility within the biotech industry.
- Business Growth and Strategic Development: The award allowed the CEO to fully dedicate her time to the company, significantly improving our business plan and marketing strategy. This focused effort and the ability to hire specialised consultants refined our go-to-market approach, positioning us more competitively in companion diagnostics.
- Networking and Industry Visibility: Through participation in numerous pitching competitions and international events, such as 4YFN in Barcelona and HLTH Europe, expressTEC substantially increased its visibility among investors and key opinion leaders. This exposure has been instrumental in establishing expressTEC as a key player in companion diagnostics.
- Patent Submissions: To protect our innovative technology, expressTEC has filed patent applications in crucial global markets, including the US, Canada, Brazil, and Japan. These submissions safeguard our intellectual property and strategically position us in markets essential to our product’s success.
- Mentoring and Coaching: Participation in mentoring and coaching programs, especially those provided by the EIC, has significantly enhanced our team’s business, financial, and market analysis skills. This expert guidance has been essential in navigating the complexities of biotech entrepreneurship.
- Investment and Resource Acquisition: expressTEC secured vital funding, including €100K from Portugal Ventures and over €65K in pitching awards. These funds were pivotal in advancing our research and development efforts and enhancing our visibility within the biotech industry.
- Business Growth and Strategic Development: The award allowed the CEO to fully dedicate her time to the company, significantly improving our business plan and marketing strategy. This focused effort and the ability to hire specialised consultants refined our go-to-market approach, positioning us more competitively in companion diagnostics.
- Networking and Industry Visibility: Through participation in numerous pitching competitions and international events, such as 4YFN in Barcelona and HLTH Europe, expressTEC substantially increased its visibility among investors and key opinion leaders. This exposure has been instrumental in establishing expressTEC as a key player in companion diagnostics.
- Patent Submissions: To protect our innovative technology, expressTEC has filed patent applications in crucial global markets, including the US, Canada, Brazil, and Japan. These submissions safeguard our intellectual property and strategically position us in markets essential to our product’s success.
- Mentoring and Coaching: Participation in mentoring and coaching programs, especially those provided by the EIC, has significantly enhanced our team’s business, financial, and market analysis skills. This expert guidance has been essential in navigating the complexities of biotech entrepreneurship.
The progress made by expressTEC under the Women TechEU Award has positioned the company at the forefront of scientific and business innovation in the field of personalized cancer therapy. Our RNA-based diagnostics technology represents a significant advancement beyond current methodologies based on DNA, with the potential to dramatically transform how cancer treatment is personalized. The strategic filing of patents across key international markets further bolsters our competitive edge and ensures that our innovative solutions are well-protected. These accomplishments reinforce our leadership in the field and lay the groundwork for continued advancements that could significantly impact cancer treatment and patient care.
As expressTEC moves forward, we remain committed to further developing our technologies, expanding our market presence, and bringing life-changing innovations to cancer patients worldwide.
As expressTEC moves forward, we remain committed to further developing our technologies, expanding our market presence, and bringing life-changing innovations to cancer patients worldwide.